


Inpatient Clinical Pathway for Children with Skin Soft Tissue Infection



Antibiotic Recommendations

| | Non-purulent (<i>S. pyogenes</i> , MSSA) | Purulent (or MRSA risk factors*) (<i>S. aureus</i>) | Duration |
|--|---|--|--|
| Outpatient (ED discharge or transition IV to PO) | <p>First line:</p> <p>PO Cephalexin 50 mg/kg/day divided TID (max 500 mg/dose)</p> <p>Cephalosporin allergy:</p> <p>PO Clindamycin 10 mg/kg/dose TID (max 600 mg/dose)</p> | <p>First line:</p> <p>PO Bactrim 5 mg TMP/kg/dose BID (max 160 mg TMP/dose)</p> <p>Sulfa allergy:</p> <p>PO Clindamycin 10 mg/kg/dose TID (max 600 mg/dose)</p> <p>Third line (only ≥ 8 years old):</p> <p>25-45kg: PO Doxycycline 50 mg BID (50 mg capsules)</p> <p>>45kg: Doxycycline 100mg BID (100mg capsules)</p> | <p>5-7 days</p> <p>Follow up with PCP before stopping antibiotics</p> |
| Inpatient (ED admission) | <p>First line:</p> <p>IV Cefazolin 100 mg/kg/day divided Q8H (max 2 g/dose)</p> <p>Cephalosporin allergy:</p> <p>IV Clindamycin 13 mg/kg/dose Q8H (max 900 mg/dose)</p> <p>Severe:</p> <p>IV Vancomycin 15 mg/kg/dose Q6H (max 3.6 g/day) Consult Pharmacy to dose, consult Peds ID prior to use</p> | <p>First line:</p> <p>PO Bactrim 5 mg TMP/kg/dose Q12H (max 160 mg TMP/dose)</p> <p>Second line:</p> <p>IV Clindamycin 13 mg/kg/dose Q8H (max 900 mg/dose)</p> <p>Severe:</p> <p>IV Vancomycin 15 mg/kg/dose Q6H (max 3.6 g/day) Consult Pharmacy to dose, consult Peds ID prior to use</p> | <p>5-7 days</p> <p>Follow up with PCP before stopping antibiotics</p> |

*MRSA risk factors: Personal or family history, close/household contact, penetrating trauma, recurrent pustules/boils, IV drug use and failed Cephalexin > 48 hours

Pathogen Susceptibility

| | <i>S. pyogenes</i> | MSSA | MRSA (19% of <i>S. aureus</i>) |
|------------------------------|---------------------------|-------------|---------------------------------------|
| Cefazolin, Cephalexin | 100 | 100 | 0 |
| Clindamycin | 94 | 71 | 65 |
| TMP-SMX | n/a | 99 | 98 |
| Doxycycline | n/a | n/a | n/a |
| Vancomycin | 100 | 100 | 100 |

Updated: 2020 Lurie antibiogram

Literature

1. Jaggi P, Wang L, Gleeson S, Moore-Clingenpeel M, Watson JR. Outpatient antimicrobial stewardship targets for treatment of skin and soft-tissue infections. *Infect Control Hosp Epidemiol*. 2018;39(8):936-940. doi:10.1017/ice.2018.124
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children [published correction appears in *Clin Infect Dis*. 2011 Aug 1;53(3):319]. *Clin Infect Dis*. 2011;52(3):e18-e55. doi:10.1093/cid/ciq146
3. Nelson CE, Chen A, McAndrew L, Tay KY, Balamuth F. Management of Skin and Soft-Tissue Infections Before and After Clinical Pathway Implementation. *Clin Pediatr (Phila)*. 2018;57(6):660-666. doi:10.1177/0009922817738329
4. Schuler CL, Courter JD, Conneely SE, et al. Decreasing Duration of Antibiotic Prescribing for Uncomplicated Skin and Soft Tissue Infections. *Pediatrics*. 2016;137(2):e20151223. doi:10.1542/peds.2015-1223
5. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published correction appears in *Clin Infect Dis*. 2015 May 1;60(9):1448. Dosage error in article text]. *Clin Infect Dis*. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444
6. Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess. *N Engl J Med*. 2016;374(9):823-832. doi:10.1056/NEJMoa1507476
7. Trenchs V, Hernandez-Bou S, Bianchi C, Arnan M, Gene A, Luaces C. Blood Cultures Are Not Useful in the Evaluation of Children with Uncomplicated Superficial Skin and Soft Tissue Infections. *Pediatr Infect Dis J*. 2015;34(9):924-927. doi:10.1097/INF.0000000000000768
8. Zwemer E, Stephens JR. Things We Do For No Reason: Blood Cultures for Uncomplicated Skin and Soft Tissue Infections in Children. *J Hosp Med*. 2018;13(7):496-499. doi:10.12788/jhm.2984
9. Children's Hospital of Philadelphia, L. McAndrew, MD; S. Helman, MSN; C. Christian, MD; L. Utidjian, MD, September 2020. Inpatient Cellulitis/Abscess Pathway. Available from: <https://www.chop.edu/clinical-pathway/cellulitis-abscess-suspected-inpatient-care-clinical-pathway>.